رجوع

Watch Compare

Nasus Pharma Ltd

جودة البيانات: 100%

NSRX

NYSE Manufacturing Chemicals

KWD 2.26

▼ KWD 0.08 (-3.42%)

القيمة السوقية: 26.47 M

السعر

KWD 2.26

القيمة السوقية

26.47 M

نطاق اليوم

KWD 2.25 — KWD 2.36

نطاق 52 أسبوعًا

KWD 1.98 — KWD 9.99

حجم التداول

16,404

فتح KWD 2.32

متوسط 50 يوم / 200 يوم

KWD 4.48

49.56% below

متوسط 50 يوم / 200 يوم

KWD 6.57

65.61% below

Quick Summary

النقاط الرئيسية

Negative free cash flow of -4.93 M

Capital efficient — spends only 0.00% of revenue on capex

النمو

Revenue Growth (5Y)

N/A

Revenue (1Y)N/A

Earnings (1Y)N/A

FCF Growth (3Y)N/A

الجودة

Return on Equity

-211.56%

أقل من متوسط القطاع (-51.02%)

ROIC-136.37%

Net Margin-0.47%

Op. Margin-0.40%

الأمان

Debt / Equity

N/A

Current Ratio0.06

Interest Coverage-62.87

التقييم

PE (TTM)

-4.52

أقل من متوسط القطاع (-1.98)

P/B RatioN/A

EV/EBITDAN/A

Dividend YieldN/A

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Manufacturing (44 نظير)

المقياس	السهم	وسيط القطاع
P/E	-4.5	-2.0
P/B	—	5.1
ROE %	-211.6	-51.0
Net Margin %	-0.5	-150.2
Rev Growth 5Y %	—	9.3
D/E	—	0.3

All Fundamental Metrics

Growth
Revenue Growth (1Y)	N/A	Revenue Growth (3Y)	N/A
Earnings Growth (1Y)	N/A	Earnings Growth (3Y)	N/A
Revenue Growth (5Y)	N/A	Earnings Growth (5Y)	N/A
Profitability
Revenue (TTM)	1.24 B	Net Income (TTM)	-5.86 M
ROE	-211.56%	ROA	-117.03%
Gross Margin	N/A	Operating Margin	-0.40%
Net Margin	-0.47%	Free Cash Flow (TTM)	-4.93 M
ROIC	-136.37%	FCF Growth (3Y)	N/A
Safety
Debt / Equity	N/A	Current Ratio	0.06
Interest Coverage	-62.87	Asset Turnover	246.80
Working Capital	-4.66 M	Tangible Book Value	-4.31 M
Dividends
Dividend Yield	N/A	Payout Ratio	N/A
Dividend Growth (3Y)	N/A	Dividend Growth (5Y)	N/A
Consecutive Div Years	N/A
Valuation
P/E Ratio	-4.52	Forward P/E	N/A
P/B Ratio	N/A	P/S Ratio	0.02
PEG Ratio	N/A	Forward PEG	N/A
EV/EBITDA	N/A	Fwd EV/EBITDA	N/A
Forward P/S	N/A	Fwd Earnings Yield	N/A
FCF Yield	-18.63%
Market Cap	26.47 M	Enterprise Value	26.26 M
Per Share
EPS (Diluted TTM)	-0.72	Revenue / Share	105.46
FCF / Share	-0.42	OCF / Share	-0.42
EPS CAGR (1Y)	N/A	EPS CAGR (5Y)	N/A
EPS CAGR (10Y)	N/A
Efficiency
CapEx / Revenue	0.00%	FCF Conversion	84.22%
SBC-Adj. FCF	-5.38 M	Growth Momentum	N/A

Income Statement

Annual, most recent first

Metric	FY2025
Revenue	1.24 B
Net Income	-5.86 M
EPS (Diluted)	-0.72
Gross Profit	—
Operating Income	-4.90 M
EBITDA	—
R&D Expenses	2.24 M
SG&A Expenses	—
D&A	—
Interest Expense	-78,000.0
Income Tax	—

Balance Sheet

Annual, most recent first

Metric	FY2025
Total Assets	5.00 M
Total Liabilities	2.24 M
Shareholders' Equity	2.77 M
Total Debt	—
Cash & Equivalents	1.24 M
Current Assets	4.86 M
Current Liabilities	2.16 M